Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Gottschlich

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Nature Nanotechnology|August 17, 2023
Programmable multispecific DNA-origami-based T-cell engagersKlaus F Wagenbauer, Nhi Pham, Adrian Gottschlich, et al.
Frontiers in Immunology|December 4, 2023
Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiologyHanna F Nowotny, Thomas Marchant Seiter, Jing Ju, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2024
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myelomaSophia Stock, Luisa Fertig, Adrian Gottschlich, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2017
Cancer cells induce interleukin-22 production from memory CD4<sup>+</sup> T cells via interleukin-1 to promote tumor growthCornelia Voigt, Peter May, Adrian Gottschlich, et al.
British Journal of Cancer|October 20, 2022
Impact of the selective A2<sub>A</sub>R and A2<sub>B</sub>R dual antagonist AB928/etrumadenant on CAR T cell functionMatthias Seifert, Mohamed-Reda Benmebarek, Daria Briukhovetska, et al.
Frontiers in Immunology|January 3, 2025
Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronismHanna F Nowotny, Tingting Zheng, Thomas Marchant Seiter, et al.
Blood Advances|February 24, 2026
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.
Leukemia|January 8, 2021
A modular and controllable T cell therapy platform for acute myeloid leukemiaMohamed-Reda Benmebarek, Bruno L Cadilha, Monika Herrmann, et al.
Blood Advances|December 1, 2025
FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell ExhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.
The New England Journal of Medicine|March 4, 2026
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid SyndromeAdrian Gottschlich, Veit Bücklein, Karim El-Marouk, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Nature Nanotechnology|August 17, 2023
Programmable multispecific DNA-origami-based T-cell engagersKlaus F Wagenbauer, Nhi Pham, Adrian Gottschlich, et al.
Frontiers in Immunology|December 4, 2023
Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiologyHanna F Nowotny, Thomas Marchant Seiter, Jing Ju, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2024
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myelomaSophia Stock, Luisa Fertig, Adrian Gottschlich, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2017
Cancer cells induce interleukin-22 production from memory CD4<sup>+</sup> T cells via interleukin-1 to promote tumor growthCornelia Voigt, Peter May, Adrian Gottschlich, et al.
British Journal of Cancer|October 20, 2022
Impact of the selective A2<sub>A</sub>R and A2<sub>B</sub>R dual antagonist AB928/etrumadenant on CAR T cell functionMatthias Seifert, Mohamed-Reda Benmebarek, Daria Briukhovetska, et al.
Frontiers in Immunology|January 3, 2025
Sex-dependent modulation of T and NK cells and gut microbiome by low sodium diet in patients with primary aldosteronismHanna F Nowotny, Tingting Zheng, Thomas Marchant Seiter, et al.
Blood Advances|February 24, 2026
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.
Leukemia|January 8, 2021
A modular and controllable T cell therapy platform for acute myeloid leukemiaMohamed-Reda Benmebarek, Bruno L Cadilha, Monika Herrmann, et al.
Blood Advances|December 1, 2025
FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell ExhaustionLisa Rohrbacher, Daniel Nixdorf, Helena Stadler, et al.
The New England Journal of Medicine|March 4, 2026
Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid SyndromeAdrian Gottschlich, Veit Bücklein, Karim El-Marouk, et al.
Pageof 4